Press Center

Despite the fact that the issue of intellectual property rights turnover is included in the perimeter of antimonopoly regulation, until recently the Russian Antitrust Agency took rather an observant position.

The regulator's position was that the issue of patent infringement is a private legal dispute between original and generic manufacturers, which should not affect the turnover of drugs, particularly the execution of contracts based on the results of public procurement. Only in isolated cases the Russian Antitrust Agency has established the fact of patent infringement and issued a corresponding order on the inadmissibility of anti-competitive practices.

Now the reverse trend has clearly emerged.

More in our update.

On 15 October, Lidings hosted a webinar for its clients to break down the legal aspects of critical information infrastructure (CII) security, focusing on the regulation applicable to the pharmaceutical and chemical (Pharma and FMCG) and healthcare industries.

On 1 September 2024, a joint order of the Ministry of Industry and Trade No. 3554 and the Ministry of Health No. 406n dated 7 August 2024 (hereinafter referred to as the “Order”) entered into force, approving a new procedure for providing the Ministry of Industry and Trade with information on medicines necessary for the purposes of licensing their production and inspecting the subjects of their circulation for compliance the requirements of good manufacturing practice. The Order replaced the previously existing procedure for interdepartmental interaction between the Ministry of Health and the Ministry of Industry and Trade.

On 9 July 2024, the State Duma passed Bill No. 638771-8 “On Introduction of the Draft Federal Law ’On Amendments to Certain Legislative Acts of the Russian Federation’” (the “Bill”) in first reading, which focuses on changes in the regulatory regime for the circulation of dietary supplements in Russia.

The proposed amendments would introduce significant changes affecting the circulation of dietary supplements and, to a certain extent, bringing it closer to the regime established for pharmaceuticals and medical devices.

The new review of the most notable patents disputes in Life Sciences in Russian and the CIS.

• pdf, 2.52 Mb

We are delighted to announce that Lidings has updated The Pharma Legal Handbook: Russia - practical directory focused on the key aspects of legislative regulation of pharmaceutical industry in Russia.

On May 14, in Moscow, Lidings held PHARMAtory - a traditional event for representatives of the pharmaceutical industry, where we discuss the most topical issues of the industry. This year the meeting took place during the Semashko Russian Pharmaceutical Forum in St. Petersburg (May 14 - 15).

Saint Petersburg will yet again host Semashko Russian Pharmaceutical Forum, a major event covering key aspects of the Russian pharmaceutical regulation. As a long-standing tradition, Lidings takes part in the Forum and supports the event as a partner.  This year, Lidings supports the online broadcast of this large-scale event.

On April 19, Moscow hosted the largest conference in the field of ophthalmology “Ophthalmology 360°. Health care, marketing, digitalization, law", which brought together leading industry experts: practicing ophthalmologists, representatives of regulatory bodies in the field of health care, specialists in the field of medical law and marketing.